Atrium Therapeutics, Inc. — fact timeline

Atrium Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

“Exhibit 99.1 Atrium Therapeutics Reports First Quarter 2026 Financial Results”

Atrium Therapeutics, Inc. entered into Transition Services Agreement with Avidity Biosciences, Inc. valued at Company and Avidity entered into a Transition Services Agreement pursuant to which Avidity will prov (effective 2026-02-26).

“☐ Item 1.01 Entry into a Material Definitive Agreement On February 26, 2026, Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs, including ATR 1086 and ATR 1072, and certain collaboration agreements, consisting of those with Bristol-Myers Squibb Company and Eli Lilly and Company, into a separate, independent publicly traded company (the “Separation”), Atrium Therapeutics, Inc.”

Atrium Therapeutics, Inc. entered into Amended and Restated License Agreement with Avidity Biosciences, Inc. valued at Company entered into an Amended and Restated License Agreement with Avidity, amending the original l (effective 2026-02-26).

“On February 26, 2026, the Company entered into an Amended and Restated License Agreement (“Amended and Restated License Agreement”) with Avidity amending the original license agreement between the Company and Avidity, dated October 25, 2025 (the “Original License Agreement”), pursuant to which the Company granted to Avidity certain exclusive and non-exclusive licenses under the Company’s platform technology and other intellectual property, and Avidity granted to the Company certain exclusive and non-exclusive licenses under certain intellectual property owned or controlled by Avidity and its subsidiaries following the Separation, as further described in the section of the Information Statement (the “Information Statement”) entitled “Business—Intellectual Property—RemainCo License Agreement” filed as Exhibit 99.1 to Amendment No. 2 to the Registration Statement on Form 10 (the “Form 10”), filed by the Company with the Securities and Exchange Commission on February 17, 2026.”

Atrium Therapeutics, Inc. completed a disposition involving Avidity Biosciences, Inc. (closed 2026-02-26).

“Avidity Biosciences, Inc. (“Avidity”) completed the previously announced separation of all of its assets and liabilities exclusively related to its early stage precision cardiology programs”